Does lacking the protective LDLR rs6511720 and PCSK9 rs11591147 alleles raise LDL cholesterol?

Genetic variations in the LDLR and PCSK9 genes profoundly influence hepatic clearance of low-density lipoprotein cholesterol (LDL-C), serving as major determinants of lifetime cardiovascular risk.

Clinical evidence

• Elevated LDL-C in non-carriers: Large-scale genome-wide association studies (GWAS) demonstrate that individuals carrying wild-type genotypes (non-carriers of the protective alleles) have significantly higher circulating LDL-C.
• Impact of protective alleles: Carrying the minor T allele of LDLR rs6511720 is associated with a 10–15% reduction in LDL-C, while the minor T (46L) allele of PCSK9 rs11591147 reduces LDL-C by 10–16% (~0.5 mmol/L). Lacking these alleles results in higher baseline circulating LDL-C.

Mechanistic pathways

• PCSK9-mediated receptor degradation: In wild-type individuals, functional PCSK9 protein binds to hepatic LDL receptors (LDLR) and targets them for lysosomal degradation. The protective PCSK9 R46L loss-of-function variant disrupts this process, preserving active cell-surface receptors.
• Reduced receptor expression: The minor allele of LDLR rs6511720 upregulates LDLR expression. Non-carriers lack this upregulation and exhibit higher PCSK9-mediated receptor degradation, resulting in fewer available receptors and diminished clearance of LDL particles from the bloodstream.

Clinical implications

• Coronary heart disease risk: Because genetic variants dictate lifelong vascular exposure to cholesterol, the elevated LDL-C levels associated with lacking these protective alleles directly increase the long-term risk of coronary heart disease.

Bottom line

• Not carrying the protective alleles in LDLR rs6511720 and PCSK9 rs11591147 results in higher circulating LDL-C, driven mechanically by reduced hepatic LDL receptor expression and increased receptor degradation.